Wow. That’s an interesting PR and pivot from
Post# of 11802
That’s an interesting PR and pivot from Berman and DECN. I applaud the strategy.
As for the long term direction and potential M&A, that’s another sound and winning business strategy IMO. Value of any emerging bio-type company is at its highest after regulatory approval. Leverage in negotiation shifts to seller.
If it happens, I assume the repurchase of the diabetes platform would have Berman take the company private? That’s why most initially invested here and I continue to wait and hope for a low cost and effective solution for the diabetes afflicted; esp. younger children. This one is personal at my end.
So much going on you just can’t make this stuff up!
Make it happen, DECN!